What caused the GNCA stock drop pre-market?

The drop reflects extreme illiquidity, legacy Chapter 11 restructuring from July 2022, and no recent positive clinical or financing news. Low float magnifies percent moves; volume today was 30,268 versus avg 80,568.

What is the Meyka AI grade for GNCA stock?

Meyka AI rates GNCA at **58.55** out of 100, Grade **C+**, suggestion **HOLD**. The score factors in benchmark and sector comparison, financial growth, key metrics, and analyst consensus.

Does Meyka AI provide a forecast for GNCA stock?

Yes. Meyka AI's forecast model projects a cautious one-year price of **$0.0010** versus current **$0.0001**, implying a potential **+900.00%** upside in a recovery scenario. Forecasts are model-based and not guarantees.

Is GNCA stock a buy for long-term investors?

Given bankruptcy history, near-zero pricing, and clinical uncertainty, GNCA stock is high risk. Long-term buying requires conviction in restructuring outcomes and deep due diligence on filings and assets.

US Stocks

GNCA (Genocea Biosciences, Inc.) NASDAQ down 97.44% pre-market 23 Jan 2026: Key signals for traders

ByDanny Kontos January 23, 2026January 23, 2026

GNCA stock opened the pre-market session at $0.0001, trading down 97.44% on NASDAQ on 23 Jan 2026 on thin volume of 30,268 shares. This extreme move follows a long decline from a 52-week high of $1.45, and reflects severe liquidity stress and legacy restructuring from a Chapter 11 filing. Investors tracking Genocea Biosciences, Inc. (GNCA) should note the stock’s near-zero market cap reading and the gap between short-term averages: 50-day average price $0.00472 and 200-day average price $0.11462. We provide a concise GNCA stock analysis, risks, Meyka AI grade, and a model forecast for traders.